Biotech · Public company · Berkeley Heights, NJ, US

Tonix Pharmaceuticals Holding Corp.

Ticker TNXP · SEC CIK 0001430306

Track this companyFree. Adds Tonix Pharmaceuticals Holding Corp. to your Dealase workspace and tells you when its record changes.

Clinical trials255 recruiting or active

Pipeline programs22From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline22

TNX-102 SLPhase 3 · PTSDClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SLPhase 3 · FibromyalgiaClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SL 5.6 mgPhase 3 · PTSDClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SL Tablet 2.8 mgPhase 3 · Primary FibromyalgiaClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SL Tablet, 2.8 mgPhase 3 · FibromyalgiaClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SL Tablet, 2.8mgPhase 3 · FibromyalgiaClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SL Tablet, 5.6 mgPhase 3 · FibromyalgiaClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SLPhase 2 · Major Depressive Episode (MDE)ClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SLPhase 2 · Post-Acute Sequelae of SARS-CoV-2 (PASC) InfectionClinicalTrials.gov · fetched Nov 12, 2026
TNX-1300Phase 2 · Cocaine IntoxicationClinicalTrials.gov · fetched Nov 12, 2026
TNX-1300 (Injection)Phase 2 · Cocaine UseClinicalTrials.gov · fetched Nov 12, 2026
TNX-1900Phase 2 · Chronic MigraineClinicalTrials.gov · fetched Nov 12, 2026
TNX-601 ERPhase 2 · DepressionClinicalTrials.gov · fetched Nov 12, 2026
Usual CarePhase 2 · Cocaine IntoxicationClinicalTrials.gov · fetched Nov 12, 2026
CANDINPhase 1 · Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
DiluentPhase 1 · Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
Keyhole Limpet Hemocyanin (KLH)Phase 1 · Phase 1 First-in-human Study Involving Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
TNX-102 SLPhase 1 · Healthy Subjects (HS)ClinicalTrials.gov · fetched Nov 12, 2026
TNX-1500Phase 1 · Phase 1 First-in-human Study Involving Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
TNX-2110Phase 1 · Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
TNX-2120Phase 1 · Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026
TNX-2130Phase 1 · Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2ClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

(TNX-1500) in Kidney Transplant RecipientsPHASE2 · NOT_YET_RECRUITING · started Jan 1, 2027ClinicalTrials.gov NCT07204080 · fetched Nov 12, 2026
Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary SurgeryPHASE2 · RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07730294 · fetched Nov 12, 2026
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)PHASE2 · RECRUITING · started Jun 25, 2026ClinicalTrials.gov NCT07621237 · fetched Nov 12, 2026
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin DeficiencyPHASE1 · RECRUITING · started Sep 10, 2025ClinicalTrials.gov NCT04789148 · fetched Nov 12, 2026
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)PHASE2 · RECRUITING · started Mar 25, 2025ClinicalTrials.gov NCT06636786 · fetched Nov 12, 2026
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)PHASE2 · TERMINATED · started Aug 16, 2024ClinicalTrials.gov NCT06045793 · fetched Nov 12, 2026
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy SubjectsPHASE1 · COMPLETED · started Jul 18, 2023ClinicalTrials.gov NCT07473752 · fetched Nov 12, 2026
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)PHASE2 · COMPLETED · started Mar 2, 2023ClinicalTrials.gov NCT05686408 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigrainePHASE2 · COMPLETED · started Dec 6, 2022ClinicalTrials.gov NCT05679908 · fetched Nov 12, 2026
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 InfectionPHASE2 · COMPLETED · started Aug 18, 2022ClinicalTrials.gov NCT05472090 · fetched Nov 12, 2026
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaPHASE3 · COMPLETED · started Apr 6, 2022ClinicalTrials.gov NCT05273749 · fetched Nov 12, 2026
A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese SubjectsPHASE1 · COMPLETED · started Mar 18, 2022ClinicalTrials.gov NCT07464535 · fetched Nov 12, 2026
Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide AntigensPHASE1 · TERMINATED · started Jan 7, 2022ClinicalTrials.gov NCT05216510 · fetched Nov 12, 2026
An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) SubjectsPHASE2 · WITHDRAWN · started Sep 3, 2021ClinicalTrials.gov NCT04996056 · fetched Nov 12, 2026
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaPHASE3 · COMPLETED · started Jul 22, 2020ClinicalTrials.gov NCT04508621 · fetched Nov 12, 2026
A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaPHASE3 · COMPLETED · started Dec 9, 2019ClinicalTrials.gov NCT04172831 · fetched Nov 12, 2026
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSDPHASE3 · TERMINATED · started Mar 7, 2019ClinicalTrials.gov NCT03841773 · fetched Nov 12, 2026
A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSDPHASE3 · COMPLETED · started Apr 19, 2018ClinicalTrials.gov NCT03508700 · fetched Nov 12, 2026
12-Week Open-Label Extension Study of TNX-102 SL in PTSD PatientsPHASE3 · TERMINATED · started Jun 20, 2017ClinicalTrials.gov NCT03110575 · fetched Nov 12, 2026
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSDPHASE3 · TERMINATED · started Mar 27, 2017ClinicalTrials.gov NCT03062540 · fetched Nov 12, 2026
Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With FibromyalgiaPHASE3 · TERMINATED · started Jul 22, 2016ClinicalTrials.gov NCT02829814 · fetched Nov 12, 2026
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia PatientsPHASE3 · COMPLETED · started Aug 4, 2015ClinicalTrials.gov NCT02589275 · fetched Nov 12, 2026
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related ConditionsPHASE2 · COMPLETED · started Apr 14, 2015ClinicalTrials.gov NCT02421679 · fetched Nov 12, 2026
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgiaPHASE3 · COMPLETED · started Apr 1, 2015ClinicalTrials.gov NCT02436096 · fetched Nov 12, 2026
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related ConditionsPHASE2 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02277704 · fetched Nov 12, 2026

SEC filings12

10-Q · QUARTERLY REPORTSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 2, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 8, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 18, 2026 · fetched Nov 12, 2026
10-Q · QUARTERLY REPORTSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 3, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 21, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 13, 2026 · fetched Nov 12, 2026

NIH awards1

Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine IntoxicationFiscal year 2025 · $605.8KNIH RePORTER 5U01DA056245-03 · fetched Nov 12, 2026